Diversified Consumer Services
Company Overview of University of Florida
University of Florida is an educational and research institution. The institute provides associate, bachelors, masters, doctoral, and professional degrees in the languages, arts, sciences, engineering, media, distance education, and part time programs. University of Florida was founded in 1853 and is based in Gainesville, Florida.
219 Grinter Hall
PO Box 115500
Gainesville, FL 32611-5500
Founded in 1853
Key Executives for University of Florida
Senior Vice President of Health Affairs
Senior Vice President of Agriculture and Natural Resources
Dean of College of Public Health and Health Professions
Founding Chairwoman for Department of Epidemiology
Compensation as of Fiscal Year 2014.
University of Florida Key Developments
University of Florida Announces Board Appointments
Feb 18 15
Govenor Rock Scott named Tampa Trenam Kemker Shareholder Robert Stern to the University of Florida's Board of Trustees. Stern will serve a five-year term working with other board members to oversee the university's facilities and program needs. Scott also named Rahul Patel of Atlanta to the board.
University of Florida Presents at BioFlorida Annual Conference, Oct-12-2014 through Oct-14-2014
Oct 11 14
University of Florida Presents at BioFlorida Annual Conference, Oct-12-2014 through Oct-14-2014. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Presentation Date & Speakers: Oct-13-2014, Steve Anton, Associate Professor & Chief, Clinical Research Division. Oct-14-2014, Julie Bradley, Faculty Member, Department of Radiation Oncology.
Genzyme Collaborates with University of Florida and The University of Pennsylvania on Gene Therapy for Rare Disease that Causes Childhood Blindness
Sep 24 14
Genzyme announced the establishment of a research collaboration with the University of Florida and the University of Pennsylvania to develop a gene therapy for the treatment of a rare genetic disease that causes childhood blindness. Leber congenital amaurosis type 1 (LCA-1) is usually diagnosed in children who are less than a year old, and patients remain severely visually impaired for the rest of their lives. Genzyme is providing $900,000 in funding over three years to Dr. Shannon Boye, assistant professor of ophthalmology at the University of Florida, to fund her LCA-1 research. Dr. Boye's research is focused on a gene called guanylate cyclase (GUCY2D) that is mutated in LCA-1 patients. The GUCY2D gene normally makes GC1, a protein expressed in photoreceptors, which are located in the retina of the eye and convert light into electrical signals that the brain interprets as vision. Genzyme's funding supplements current funding from the Foundation Fighting Blindness. The majority of the early stage LCA-1 research is being conducted at the University of Florida, with Genzyme taking on increasingly more activities as the program advances toward clinical trials. Genzyme has the option to in-license the potential treatment before it enters clinical trials. The gene therapy is administered by inserting a healthy copy of the GUCY2D gene into the eye. The healthy gene is put into an adeno associated viral (AAV) vector whose viral DNA has already been removed. The viral vector is injected into the retina and transfers the healthy gene to the photoreceptors, with the goal of treating the disease with a single treatment. Treating physicians of LCA-1 patients from the University of Pennsylvania are also playing a key role in this research. They provide information to the University of Florida and Genzyme about indicators to look for in trials to know whether or not the therapy is working. They are also conducting a natural history study, which tracks how the retina of an LCA-1 patient progresses over time if untreated.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|